Streetbeat News

Regulatory

LTRN

Lantern Pharma Inc. (NASDAQ:LTRN) has announced the first patient dosing in the Phase 1 clinical trial for LP-184, a potential therapy for advanced solid tumors. The drug, developed with Lantern's AI Platform, RADR®, has a global aggregate market potential of approximately $11-13 billion. The Phase 1 trial is assessing the safety and tolerability of escalating doses of LP-184 in patients with advanced solid tumors and recurrent high-grade gliomas. Lantern plans to advance LP-184 into additional clinical trials after the Phase 1 trial.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:32 pm

RNAZ

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced positive pre-clinical results for its lead therapeutic candidate, TTX-MC138, in treating glioblastoma multiforme (GBM) tumors. The candidate was delivered to brain tumors and effectively engaged its target. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit the oncogenic RNA, microRNA-10b. The company's first-in-human clinical trial with TTX-MC138 is open for enrollment and has dosed its first patient.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:31 pm

ENOV

Enovis Corp (NYSE:ENOV) has agreed to acquire LimaCorporate S.p.A. for an enterprise value of approximately €800 million ($850 million). The acquisition will expand ENOV's international presence and product mix, and is expected to create a $1 billion revenue reconstruction business. The deal is expected to be completed in early FY24, subject to regulatory approvals. The company expects the acquisition to be neutral to slightly accretive to FY24 adjusted earnings per share and accretive in FY25 and beyond.

Portfolio Pulse from Lekha Gupta

September 25, 2023 | 12:28 pm

SCYX

Shares of SCYNEXIS have been halted due to pending news. Further details are yet to be released.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:26 pm

BTCUSD

ETHUSD

Ray Youssef, CEO of Paxful, a peer-to-peer global finance platform, criticized Bitcoin influencers, stating that '99.9% of Bitcoin influencers are fake'. He suggested that these influencers secretly promote lesser-known cryptocurrencies, which he referred to as 'shi*coins'. Paxful, founded by Youssef and Artur Schaback in 2015, initially supported trading in multiple cryptocurrencies, including Bitcoin and Ether, but suspended Ether trading due to its transition from a proof-of-work to a proof-of-stake network consensus mechanism.

Portfolio Pulse from Mehab Qureshi

September 25, 2023 | 12:22 pm

BCLI

The FDA has stated that it does not believe there is sufficient evidence to support that any of the assessed biomarkers for Brainstorm Cell Therapeutics' ALS therapy is reasonably likely to predict clinical benefit. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:21 pm

BCLI

The FDA staff has expressed skepticism about the efficacy of Brainstorm Cell Therapeutics' ALS therapy, stating that they do not believe there is sufficient evidence to support that any of the assessed biomarkers for the therapy is reasonably likely to predict clinical benefit.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:14 pm

HYMC

Hycroft Mining Holding Corporation (NASDAQ:HYMC) plans to file a request for a hearing before the Nasdaq Hearings Panel to present its plan to regain compliance with Nasdaq's minimum bid price requirement. The company's shares will continue to trade on Nasdaq until the Panel's decision is issued.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:07 pm

PDSB

PDS Biotechnology has announced that its Key Opinion Leader Roundtable on addressing current and future treatments for recurrent/metastatic human papillomavirus-positive head and neck squamous cell carcinoma and the potential application of PDS0101 will take place on October 3. The event was originally scheduled for September 27, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:05 pm

BIOR

Biora Therapeutics has submitted an Investigational New Drug (IND) application to the US FDA for its BT-600 program. The application supports the next phase of development of BT-600, a drug/device combination designed to use Biora's NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:01 pm